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licenseThe benefit of individualized low-dose human chorionic
gonadotropin support for high responders in gonadotropin-releasing
hormone agonist-triggered in-vitro fertilization/intracytoplasmic
sperm injection cyclesOvarian hyperstimulation syndrome (OHSS) is one of the
major complications in artificial reproductive technology,
especially in high responders. Exogenous human chorionic
gonadotropin (hCG) for triggering final oocyte maturation
during controlled ovarian stimulation (COS) is primarily
responsible for the pathogenesis of early-onset OHSS.1 Sev-
eral strategies were offered to prevent OHSS, including
reducing the gonadotropin dose, individualizing in-vitro fer-
tilization/intracytoplasmic sperm injection (IVF/ICSI) treat-
ment protocols, using adjuvant metformin therapy, and further
considering alternatives for triggering ovulation, coasting,
cryopreservation of embryos, avoiding hCG for luteal phase
support (LPS), cryopreservation of embryos, albumin infusion,
cabergoline administration, and others.1 Recently,
gonadotropin-releasing hormone agonist (GnRHa) used to
induce final oocyte maturation and ovulation presented an
alternative to hCG to effectively reduce OHSS risk in COS.
The Cochrane Review revealed that GnRHa trigger was
associated with a lower incidence of OHSS than was hCG
[odds ratio (OR) 0.15, 95%, confidence interval (CI)
0.05e0.47].2 However, the critical disadvantage of GnRHa
trigger is early luteolysis and consequently luteal phase
insufficiency, resulting in impaired endometrial receptivity and
worse conception rates. The Cochrane Review indicated that
GnRHa trigger was associated with a lower ongoing preg-
nancy rate (OR 0.70, 95% CI 0.54e0.91) and a higher early
miscarriage rate (OR 1.74, 95% CI 1.10e2.75) than was seen
with hCG.2 To improve reproductive outcomes in GnRHa
trigger protocol, some strategies of modified LPS were sug-
gested as follows3: (1) intensive LPS with aggressive exoge-
nous administration of estradiol (E2) and progesterone (P)4;
(2) dual trigger with both GnRHa and low-dose hCG5; and (3)
hCG rescue after oocyte retrieval.6 All approaches have been
shown to be effective in generating pregnancy rates similar to
conventional hCG trigger and leading to a very low OHSS
risk.7 However, combined modified LPS in GnRHa trigger
protocol seems to be popular in Taiwan.8x.doi.org/10.1016/j.jcma.2016.03.004
901/Copyright © 2016, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The study by Huang and colleagues9 in this issue of the
Journal of the Chinese Medical Association presented a pro-
tocol of GnRHa trigger with individualized low-dose hCG
support and intensive LPS. The authors concluded that the
protocol provides satisfactory pregnancy rate with an
extremely low OHSS risk, and emphasized that individualized
low-dose hCG supply may provide a patient-friendly method
for LPS.9 The individualized low-dose hCG supply in the
study of Huang et al9 represented hCG for ovulation triggering
with a dose depending on the serum level of E2 and the
number of follicles  11 mm on the trigger day (500 IU for
cycles with peak E2 > 5000 pg/mL or follicle number  25;
750 IU for cycles with peak E2 3500e5000 pg/mL and follicle
number < 25; and 1000 IU for cycles with peak E2 < 3500 pg/
mL and follicle number < 25) and hCG for luteal rescue with
an additional 300 IU of hCG, which was administered if the
serum E2 level dropped to < 800 pg/mL before the sixth day
of oocyte retrieval. The authors found no OHSS cases occur-
red in this protocol, with even more high responders in the
group.9 When compared with a protocol of GnRHa trigger
alone with intensive LPS, the authors observed that GnRHa
trigger with individualized low-dose hCG support and inten-
sive LPS had a tendency toward improved pregnancy out-
comes. The authors provided an explanation for the result. In
addition to the apparent benefit to LPS, the authors suggested
that dual trigger seemed to contribute to better oocyte matu-
ration than GnRHa trigger alone. However, a significantly
higher fertilization rate found in the protocol of GnRHa trigger
with individualized low-dose hCG supplementation supported
the idea9; nonetheless, more studies are needed to confirm the
result. In contrast, the authors provided the criteria for hCG
trigger dosage according to serum E2 level and the number of
follicles  11 mm on trigger day. Moreover, the authors rec-
ommended hCG rescue with an additional 300 IU of hCG
from their own experience.9 These criteria have given us a
great reference in clinical practice. However, more studies
have to be undertaken to verify the criteria.sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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ration with a bolus of GnRHa can be effective in the prevention
ofOHSS.However, no consensus onGnRHa trigger type or dose
emerged. A randomized investigator-blinded trial compared
different dosage of triptorelin (Ipsen, Paris, France; 0.2 mg,
0.3 mg, and 0.4 mg) for ovulation trigger and found that there
were no significant differences in the number of mature oocytes
and top-quality embryos between triptorelin doses of 0.2 mg,
0.3 mg, and 0.4 mg.10 However, more studies are needed to
explore the issue. GnRHa trigger with modified LPS provided
satisfactory pregnancy rate. Studies have shown that the early
luteal phase steroid levels and the endometrial gene expression
following GnRHa trigger and modified LPS were similar to
those seen after hCG trigger.11 Therefore, modified LPS is
necessary for GnRHa as an oocyte for final maturation and
ovulation trigger, but likewise, there is no consensus on this
point. Engmann and colleagues12 indicated that GnRHa trigger
and LPS with intramuscular (IM) P and E2 patch provided a
similar pregnancy rate to hCG trigger. The study conducted by
Griffin et al5 revealed that dual trigger with GnRHa and 1000 IU
hCG and LPSwith IM P and E2 patch obtained better pregnancy
outcome than GnRHa trigger alone. Two prospective random-
ized controlled multicenter studies demonstrated that a GnRHa
trigger followed by early luteal hCG support with one bolus of
1.500 IU hCG appeared to achieve a pregnancy rate similar to
that with traditional hCG trigger.6,13 Severe early OHSS can still
occur when low-dose hCG is used for luteal rescue.14 Devel-
opment of individualized LPS regimens in the GnRHa trigger
protocol is required. In the study by Huang and colleagues,9 a
protocol of GnRH agonist trigger with individualized low-dose
hCG support and intensive LPS was proposed. Additionally,
Engmann and co-authors15 recommended an LPS protocol after
GnRHa trigger as follows: intensive LPS with transdermal E2
and IM P alone if peak serum E2 is 4000 pg/mL after GnRHa
trigger; dual trigger with GnRHa and hCG 1000 IU if peak
serum E2 is < 4000 pg/mL; hCG 1500 IU 35 h after GnRHa
trigger if there are < 25 follicles; and freeze all oocytes or
embryos if there are > 25 follicles.
In conclusion, OHSS, primarily stemming from hCG trig-
ger, is a potentially life-threatening complication during COS.
Instead of conventional hCG trigger, GnRHa for induction of
final oocyte maturation and ovulation significantly reduces
OHSS risk. Through overcoming luteal phase insufficiency,
GnRHa trigger with modified LPS can achieve a satisfactory
conception rate. Huang et al9 offered a protocol of GnRHa
trigger with individualized low-dose hCG support and inten-
sive LPS, resulting in good pregnancy outcomes and no OHSS
cases. However, optimal GnRHa type or dose and individu-
alized modified LPS regimens need to be more compre-
hensively investigated.Conflicts of interest
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